|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.630 HKD | +2.00% |
|
-4.60% | +7.28% |
| 01-23 | Sino Biopharma CEO on China's Rapid Clinical Trial Growth | MT |
| 01-14 | Sino Biopharm To Remain Active in M&A, Says Chair | MT |
| Capitalization | 104B 116B 14.9B 12.68B 11.78B 11.04B 20.57B 1,365B 21.8B 134B 53.29B 645B 55.88B 54.74B 2,359B | P/E ratio 2025 * |
23.4x | P/E ratio 2026 * | 22.3x |
|---|---|---|---|---|---|
| Enterprise value | 97.85B 109B 14.03B 11.94B 11.09B 10.4B 19.37B 1,285B 20.53B 127B 50.18B 607B 52.62B 51.55B 2,222B | EV / Sales 2025 * |
2.96x | EV / Sales 2026 * | 2.55x |
| Free-Float |
51.86% | Yield 2025 * |
1.44% | Yield 2026 * | 1.48% |
| 1 day | +2.00% | ||
| 1 week | -4.60% | ||
| Current month | +7.28% | ||
| 1 month | +2.79% | ||
| 3 months | -5.29% | ||
| 6 months | -0.90% | ||
| Current year | +7.28% |
| 1 week | 6.43 |  | 6.95 |
| 1 month | 6.13 | | 7.29 |
| Current year | 6.18 | | 7.29 |
| 1 year | 2.67 | | 9.12 |
| 3 years | 2.29 | | 9.12 |
| 5 years | 2.29 | | 9.69 |
| 10 years | 2.05 | | 11.24 |
| Manager | Title | Age | Since |
|---|---|---|---|
S Y Tse
CEO | Chief Executive Officer | 30 | 28/07/2022 |
Chun Ling Li
DFI | Director of Finance/CFO | 55 | 01/01/1996 |
Hsin Tse
IRC | Investor Relations Contact | 56 | 25/04/2013 |
| Director | Title | Age | Since |
|---|---|---|---|
Ping Tse
CHM | Chairman | 74 | 02/02/2000 |
Hsin Tse
BRD | Director/Board Member | 56 | 01/08/1995 |
| Director/Board Member | 61 | 10/04/2017 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.00% | -4.60% | +131.01% | +35.86% | 14.9B | |
| +0.82% | +5.27% | +44.22% | +214.21% | 974B | |
| +0.22% | -0.49% | +50.40% | +29.48% | 526B | |
| +0.91% | +0.63% | +28.91% | +45.81% | 385B | |
| -0.17% | -0.43% | +26.60% | +17.58% | 376B | |
| +0.51% | -3.16% | +23.19% | +23.28% | 284B | |
| +0.42% | +0.02% | +28.10% | +35.34% | 279B | |
| -1.74% | -1.61% | +14.11% | -0.69% | 271B | |
| +2.05% | +3.99% | -30.40% | -16.23% | 277B | |
| +1.01% | +5.16% | +26.93% | +31.85% | 187B | |
| Average | +0.54% | +0.83% | +34.31% | +41.65% | 357.45B | |
| Weighted average by Cap. | +0.35% | +2.06% | +30.09% | +74.59% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 33.01B 36.92B 4.73B 4.03B 3.74B 3.51B 6.53B 434B 6.93B 42.73B 16.93B 205B 17.75B 17.39B 750B | 36.04B 40.31B 5.17B 4.4B 4.09B 3.83B 7.13B 473B 7.56B 46.65B 18.49B 224B 19.38B 18.99B 818B |
| Net income | 4.73B 5.29B 679M 578M 536M 503M 936M 62.16B 993M 6.12B 2.43B 29.36B 2.54B 2.49B 107B | 4.71B 5.27B 675M 575M 534M 500M 932M 61.86B 988M 6.09B 2.42B 29.22B 2.53B 2.48B 107B |
| Net Debt | -6.06B -6.78B -869M -740M -687M -644M -1.2B -79.61B -1.27B -7.84B -3.11B -37.6B -3.26B -3.19B -138B | -12.1B -13.53B -1.74B -1.48B -1.37B -1.29B -2.39B -159B -2.54B -15.66B -6.21B -75.09B -6.51B -6.37B -275B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 6.630 $ | +2.00% | 58,249,547 |
| 22/01/26 | 6.500 $ | -1.07% | 46,184,830 |
| 21/01/26 | 6.570 $ | +1.08% | 49,422,760 |
| 20/01/26 | 6.500 $ | -0.31% | 55,241,760 |
| 19/01/26 | 6.520 $ | -6.19% | 87,072,760 |
Delayed Quote Hong Kong S.E., January 23, 2026 at 12:08 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1177 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition